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and Clinical Events in Patients
With Atrial Fibrillation
Insights From the ARISTOTLE TrialGreg Flaker, MD,* Renato D. Lopes, MD, PHD,y Elaine Hylek, MD, MPH,z Daniel M. Wojdyla, MS,y
Laine Thomas, PHD,y Sana M. Al-Khatib, MD, MHS,y Renee M. Sullivan, MD,* Stefan H. Hohnloser, MD,x
David Garcia, MD,kMichael Hanna, MD,{ John Amerena, MBBS,# Veli-Pekka Harjola, MD, PHD,** Paul Dorian, MD,yy
Alvaro Avezum, MD, PHD,zz Matyas Keltai, MD, DSC,xx Lars Wallentin, MD, PHD,kk Christopher B. Granger, MD,y
for the ARISTOTLE Committees and InvestigatorsABSTRACTBACKGROUND Amiodarone is an effective medication in preventing atrial ﬁbrillation (AF), but it interferes with the
metabolism of warfarin.
OBJECTIVES This study sought to examine the associationofmajor thrombotic clinical events andbleedingwith theuse of
amiodarone in theARISTOTLE (Apixaban forReduction inStrokeandOtherThromboembolicEvents inAtrial Fibrillation) trial.
METHODS Baseline characteristics of patients who received amiodarone at randomization were compared with those
who did not receive amiodarone. The interaction between randomized treatment and amiodarone was tested using a Cox
model, with main effects for randomized treatment and amiodarone and their interaction. Matching on the basis of a
propensity score was used to compare patients who received and who did not receive amiodarone at the time of
randomization.
RESULTS In ARISTOTLE, 2,051 (11.4%) patients received amiodarone at randomization. Patients on warfarin and
amiodarone had time in the therapeutic range that was lower than patients not on amiodarone (56.5% vs. 63.0%;
p < 0.0001). More amiodarone-treated patients had a stroke or a systemic embolism (1.58%/year vs. 1.19%/year;
adjusted hazard ratio [HR]: 1.47, 95% conﬁdence interval [CI]: 1.03 to 2.10; p ¼ 0.0322). Overall mortality and major
bleeding rates were elevated, but were not signiﬁcantly different in amiodarone-treated patients and patients not on
amiodarone. When comparing apixaban with warfarin, patients who received amiodarone had a stroke or a systemic
embolism rate of 1.24%/year versus 1.85%/year (HR: 0.68, 95% CI: 0.40 to 1.15), death of 4.15%/year versus
5.65%/year (HR: 0.74, 95% CI: 0.55 to 0.98), and major bleeding of 1.86%/year versus 3.06%/year (HR: 0.61, 95% CI:
0.39 to 0.96). In patients who did not receive amiodarone, the stroke or systemic embolism rate was 1.29%/year versus
1.57%/year (HR: 0.82, 95% CI: 0.68 to 1.00), death was 3.43%/year versus 3.68%/year (HR: 0.93, 95% CI: 0.83 to
1.05), and major bleeding was 2.18%/year versus 3.03%/year (HR: 0.72, 95% CI: 0.62 to 0.84). The interaction p values
for amiodarone use by apixaban treatment effects were not signiﬁcant.
CONCLUSIONS Amiodarone use was associated with signiﬁcantly increased stroke and systemic embolism risk and a
lower time in the therapeutic range when used with warfarin. Apixaban consistently reduced the rate of stroke and
systemic embolism, death, and major bleeding compared with warfarin in amiodarone-treated patients and patients who
were not on amiodarone. (J Am Coll Cardiol 2014;64:1541–50) © 2014 by the American College of Cardiology
Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CHADS2 = congestive heart
failure, hypertension, age,
diabetes, and stroke
CI = conﬁdence interval
HR = hazard ratio
INR = international normalized
ratio
LVEF = left ventricular ejection
fraction
MI = myocardial infarction
TIA = transient ischemic attack
TTR = time in therapeutic
range
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1542A miodarone is the most effective anti-arrhythmic drug for the preventionof atrial ﬁbrillation (AF) (1–3), and
it is recommended for patients with fre-
quent, symptomatic AF recurrences, espe-
cially in the presence of structural heart
disease (4). However, several potential draw-
backs may limit the use of amiodarone in
patients with AF.SEE PAGE 1551Warfarin is prescribed frequently to pre-
vent stroke in patients with AF. Because
amiodarone interferes with warfarin metab-
olism through the CYP 2C9 pathway, the in-
ternational normalized ratio (INR) values aremore difﬁcult to maintain in a therapeutic range of 2
to 3 (5–8). This leads to a suboptimal time in the
therapeutic range (TTR), which is associated with
increased clinical events (9,10). Noncardiovascular
side effects are also concerns with amiodarone. In
addition to well-known hepatic, thyroid, neurologic,
and ophthalmologic side effects, amiodarone occa-
sionally causes pulmonary toxicity, which may be
life-threatening (11,12), and it has also been associ-
ated with an increased risk of cancer (13–15). An
analysis from the AFFIRM (Atrial Fibrillation Follow-
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We studied the effects of amiodarone on outcomes
in the ARISTOTLE (Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrilla-
tion) trial. The ﬁrst set of objectives compared the ef-
fects of randomized apixaban or warfarin treatment
on stroke and systemic embolism, death, and bleeding
events in relation to amiodarone use at the time of
randomization. In the second set of objectives, we
compared the rates of cardiovascular death and non-
cardiovascular death in relation to amiodarone use.
METHODS
STUDY POPULATION. The design and results of the
ARISTOTLE trial have been reported (17,18). Patients
eligible for this study had AF documented on
2 occasions, at least 2 weeks apart within the
12 months before enrollment. AF was documented by
electrocardiogram or rhythm strip, Holter monitor, or
intracardiac recording, and lasted >1 minute. In
addition, at least 1 of the following risk factors for
stroke was required: age $75 years; previous stroke,
transient ischemic attack (TIA), or systemic embo-
lism; symptomatic heart failure within the pre-
vious 3 months or left ventricular ejection fraction
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1543pharmacological therapy. Key exclusion criteria were
AF due to a reversible cause, moderate or severe
mitral stenosis, conditions other than AF that
required anticoagulation (e.g., a prosthetic heart
valve), stroke within the previous 7 days, need for
aspirin >165 mg/day or for both aspirin and clopi-
dogrel, and renal insufﬁciency with a creatinine level
>2.5 mg/dl or a creatinine clearance of <25 ml/min.
RANDOMIZATION. Patients were randomized to
receive either warfarin or apixaban. Warfarin was
adjusted to achieve a target INR of 2.0 to 3.0.
Apixaban was administered in doses of 5 mg twice
daily or 2.5 mg twice daily in patients with 2
of the following criteria: age $80 years, body
weight #60 kg, or serum creatinine $1.5 mg/dl.
CLINICAL OUTCOMES. The primary efﬁcacy outcome
of the study was stroke, which as deﬁned as the
abrupt onset of a nontraumatic, focal neurological
deﬁcit lasting at least 24 h, or systemic embolism,
which was deﬁned as symptoms consistent with
acute loss of blood to a noncerebral artery conﬁrmed
by autopsy, angiography, vascular imaging, or some
other objective testing. Secondary endpoints in-
cluded myocardial infarction (MI) and death. Death
was classiﬁed as cardiovascular (stroke, systemic
embolism, MI, sudden death, heart failure, or inde-
terminate) or noncardiovascular (bleeding, malig-
nancy, infection, trauma, pulmonary). The primary
safety outcome was International Society of Throm-
bosis and Hemostasis major bleeding, which was
deﬁned as 1) bleeding that resulted in a decrease in
hemoglobin of $2 g/dl over a 24-h period; 2) bleeding
leading to a transfusion of $2 units of packed red
blood cells; 3) bleeding occurring in a critical site; or
4) bleeding leading to death. A clinical events com-
mittee blinded to treatment assignment adjudicated
all primary and secondary outcomes.
STATISTICAL ANALYSIS. The baseline characteris-
tics of those patients who received amiodarone at the
time of randomization were compared with those
who did not receive amiodarone. Continuous char-
acteristics are reported as medians and 25th and 75th
percentiles and compared using the Wilcoxon rank-
sum test. Categorical variables are reported as
frequencies and percentages and compared using
chi-square tests. Events are summarized as rates per
100 patient-years of follow-up and the number of
events. Kaplan-Meier curves were used to graphically
describe the incidence of the primary efﬁcacy and
safety events by randomized treatment and amio-
darone use at randomization. Hazard ratios (HRs)
that compared randomized treatments (apixaban vs.
warfarin) in patients on or off amiodarone werederived from Cox proportional hazards models. The
interaction between randomized treatment and
amiodarone was tested using a Cox model, with main
effects for randomized treatment and amiodarone
and their interaction. Propensity score–based match-
ing was used to compare patients on and off amio-
darone at the time of randomization. Variables
included in the propensity score were selected from
35 baseline patient characteristics believed to be
important in the selection of antiarrhythmic drug
therapy. Candidate variables for inclusion in the
propensity analysis were 1) demographic character-
istics, including age, sex, and country of enrollment;
2) medical conditions, including a history of MI, cor-
onary artery disease, pulmonary disease, intracranial
bleeding, congestive heart failure, cardiomyopathy,
valvular heart disease, congenital heart disease, un-
stable angina, diabetes mellitus, hepatic or renal
disease, ventricular ﬁbrillation and/or ventricular
tachycardia cardiac arrest, stroke and/or TIA, pe-
ripheral artery disease, noncerebral thromboembolic
event, and either carotid stent or carotid endarterec-
tomy; 3) characteristics of AF or ﬂutter, including
duration of most recent episode; 4) ﬁndings on
physical examination, including systolic blood pres-
sure and body mass index; and 5) medications at the
time of randomization, including beta-blockers and
diuretics. Each patient on amiodarone was matched
with 3 patients not on amiodarone enrolled in the
same country. Countries where amiodarone was
rarely or never used (#3 patients) were excluded from
this analysis (Finland, Malaysia, Norway, Puerto Rico,
Singapore, and Turkey). Overall, 844 patients from
these countries were excluded from this propensity
analysis. Finally, to ensure that treatment effects
with amiodarone did not vary between randomized
therapies, the tests of interactions between amio-
darone and randomized therapy were repeated with
propensity-matched samples.
All statistical analyses were performed with SAS
version 9.2 (SAS Institute, Inc., Cary, North Carolina)
and R version 3.0.1 (Vienna, Austria).
RESULTS
There were 18,201 patients enrolled in ARISTOTLE.
Amiodarone status was known at randomization in
17,907 patients; 2,051 (11%) patients received amio-
darone at randomization and 15,856 patients did
not receive amiodarone. The mean follow-up was
21.7 months for amiodarone patients and 21.8 months
for patients not on amiodarone.
There were marked geographic differences in the
use of amiodarone. Amidarone use was 17.9% in Latin
TABLE 1 Baseline Characteristics of Patients Stratiﬁed by Amiodarone Use at Randomization and Study Drug Assignment
Amiodarone No Amiodarone
p Value*
Overall
(n ¼ 2,051)
Apixaban
(n ¼ 1,009)
Warfarin
(n ¼ 1,042)
Overall
(n ¼ 15,856)
Apixaban
(n ¼ 7,954)
Warfarin
(n ¼ 7,902)
Age, yrs 68 (60, 74) 68 (61, 74) 68 (60, 74) 70 (63, 76) 70 (63, 76) 70 (63, 76) <0.0001
Age $75 yrs 481 (23.5) 228 (22.6) 253 (24.3) 5,102 (32.2) 2,569 (32.3) 2,533 (32.1) <0.0001
Female 730 (35.6) 363 (36.0) 367 (35.2) 5,598 (35.3) 2,820 (35.5) 2,778 (35.2) 0.7980
Region <0.0001
North America 291 (14.2) 151 (15.0) 140 (13.4) 291 (14.2) 2,071 (26.0) 2,065 (26.1)
Latin America 614 (29.9) 303 (30.0) 311 (29.8) 614 (29.9) 1,412 (17.8) 1,395 (17.7)
Europe 875 (42.7) 411 (40.7) 464 (44.5) 875 (42.7) 3,205 (40.3) 3,138 (39.7)
Asia Paciﬁc 271 (13.2) 144 (14.3) 127 (12.2) 271 (13.2) 1,266 (15.9) 1,304 (16.5)
Systolic BP, mm Hg 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140) 0.5417
Weight, kg 82 (71, 95) 82 (70, 95) 83 (71, 95) 82 (70, 96) 82 (70, 96) 82 (70, 96) 0.6567
BMI, kg/m2 29 (25, 33) 29 (25, 33) 29 (25, 33) 28 (25, 33) 29 (25, 33) 28 (25, 33) 0.0702
Previous stroke, TIA, or SE 321 (15.7) 165 (16.4) 156 (15.0) 3,150 (19.9) 1,552 (19.5) 1,598 (20.2) <0.0001
Previous stroke or TIA 310 (15.1) 160 (15.9) 150 (14.4) 3,059 (19.3) 128 (1.6) 1,556 (19.7) <0.0001
Previous SE 26 (1.3) 11 (1.1) 15 (1.4) 240 (1.5) 2,745 (34.5) 112 (1.4) 0.3863
HF or reduced LVEF 911 (44.4) 435 (43.1) 476 (45.7) 5,438 (34.3) 2,745 (34.5) 2,693 (34.1) <0.0001
LVEF, % 55 (42, 62) 55 (42, 62) 55 (42, 62) 56 (47, 64) 56 (47, 63) 56 (47, 64) <0.0001
Previous MI 325 (15.9) 165 (16.4) 160 (15.4) 2,229 (14.1) 1,140 (14.3) 1,089 (13.8) 0.0288
PAD 91 (4.5) 46 (4.6) 45 (4.6) 786 (5.0) 391 (33.2) 395 (5.1) 0.3056
Documented history of CAD 761 (37.2) 372 (36.9) 389 (37.4) 5,202 (32.8) 2,636 (33.2) 2,566 (32.5) <0.0001
NYHA functional class at screening <0.0001
I 912 (44.5) 443 (43.9) 469 (45.1) 8,579 (54.2) 4,250 (53.5) 4,329 (54.9)
II 839 (41.0) 415 (41.2) 424 (40.8) 5,708 (36.1) 2,899 (36.5) 2,809 (35.6)
III 284 (13.9) 145 (14.4) 139 (13.4) 1,487 (9.4) 772 (9.7) 715 (9.1)
IV 13 (0.6) 5 (0.5) 8 (0.8) 57 (0.4) 23 (0.3) 23 (0.3)
Previous PCI 164 (8.0) 83 (8.2) 81 (7.8) 1468 (9.3) 749 (9.4) 719 (9.1) 0.0616
Previous CABG 109 (5.3) 59 (5.8) 50 (4.8) 1085 (6.8) 565 (7.1) 520 (6.6) 0.0090
Previous pacemaker/ICD/
resynchronization device
200 (9.8) 102 (10.1) 98 (9.4) 1,511 (9.5) 766 (9.6) 745 (9.4) 0.7478
Hypertension requiring treatment 1,819 (88.7) 900 (89.2) 919 (88.2) 13,885 (87.6) 6,946 (87.3) 6,939 (87.3) 0.1465
Hypertrophic cardiomyopathy 46 (2.2) 23 (2.3) 23 (2.2) 396 (2.5) 196 (2.5) 200 (2.5) 0.4874
Valvular heart disease 370 (18.1) 201 (20.0) 169 (16.2) 2,828 (17.8) 1,407 (17.7) 1,421 (18.0) 0.8147
Congenital heart disease 38 (1.9) 20 (2.0) 18 (1.7) 250 (1.6) 130 (1.6) 120 (1.5) 0.3476
Admitted with unstable angina 198 (9.7) 107 (10.6) 91 (8.7) 1,295 (8.2) 644 (8.1) 651 (8.2) 0.0213
Cardiac arrest (VT/VF) 23 (1.1) 10 (1.0) 13 (1.2) 121 (0.8) 60 (0.8) 61 (0.8) 0.0868
Previous clinically relevant or
spontaneous bleeding
282 (13.8) 139 (13.8) 143 (13.7) 2,733 (17.2) 1,371 (17.2) 1,362 (17.2) <0.0001
Previous intracranial bleeding 12 (0.6) 4 (0.4) 8 (0.8) 89 (0.6) 44 (0.6) 45 (0.6) 0.8914
History of fall within previous year 71 (4.0) 44 (5.0) 27 (3.0) 680 (4.7) 340 (4.7) 340 (4.7) 0.1740
History of pulmonary disease 354 (17.3) 168 (16.7) 186 (17.9) 3,007 (19.0) 1,507 (19.0) 1,500 (19.1) 0.0628
Diabetes 448 (21.8) 234 (23.2) 214 (20.5) 4,052 (25.6) 2,028 (25.5) 2,024 (25.6) 0.0003
History of thyroid disease 214 (10.5) 110 (10.9) 104 (10.0) 1,811 (11.4) 934 (11.8) 877 (11.1) 0.1894
Type of AF <0.0001
Paroxysmal 701 (34.2) 343 (34.0) 358 (34.4) 2,035 (12.8) 1,006 (12.7) 1,029 (13.0)
Persistent or permanent 1,350 (65.8) 666 (66.0) 684 (65.6) 13,818 (87.2) 6,946 (87.3) 6,872 (87.0)
Time from ﬁrst occurrence of AF, mo <0.0001
<6 625 (30.6) 301 (29.9) 324 (31.2) 4,302 (27.2) 2,152 (27.1) 2,150 (27.3)
6–24 437 (21.4) 207 (20.6) 230 (22.2) 3,016 (19.1) 1,533 (19.3) 1,483 (18.8)
>24 983 (48.1) 499 (49.6) 484 (46.6) 8,487 (53.7) 4245 (53.5) 4,242 (53.9)
Duration of most recent episode, day <0.0001
<1 103 (5.1) 54 (5.5) 49 (4.8) 571 (3.6) 289 (3.6) 282 (3.6)
1 422 (20.9) 214 (21.6) 208 (20.3) 1,889 (12.0) 957 (12.1) 932 (11.9)
2–5 156 (7.7) 80 (8.1) 76 (7.4) 657 (4.2) 334 (4.2) 323 (4.1)
6–13 111 (5.5) 54 (5.5) 57 (5.6) 618 (3.9) 328 (4.2) 290 (3.7)
$14 1,223 (60.7) 588 (59.4) 635 (62.0) 11,988 (76.2) 5,978 (75.8) 6,010 (76.7)
Continued on the next page
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TABLE 1 Continued
Amiodarone No Amiodarone
p Value*
Overall
(n ¼ 2,051)
Apixaban
(n ¼ 1,009)
Warfarin
(n ¼ 1,042)
Overall
(n ¼ 15,856)
Apixaban
(n ¼ 7,954)
Warfarin
(n ¼ 7,902)
History of cardioversion 449 (21.9) 233 (23.1) 216 (20.7) 1,346 (16.9) 1,278 (16.2) <0.0001
Previous use of VKA for >30 days 998 (48.7) 484 (48.0) 514 (49.3) 9,274 (58.5) 4,659 (58.6) 4,615 (58.4) <0.0001
CHADS2 2.0  1.0 2.0  1.0 2.0  1.1 2.1  1.1 2.1  1.1 2.1  1.1 0.0003
CHADS2 score 0.0008
#1 734 (35.8) 351 (34.8) 383 (36.8) 5,317 (33.5) 2,674 (33.6) 2,643 (33.4)
2 769 (37.5) 380 (37.7) 389 (37.3) 5,660 (35.7) 2,838 (35.7) 2,822 (35.7)
CHA2DS2-VASc score 3.2  1.5 3.3  1.5 3.2  1.5 3.4  1.5 3.4  1.5 3.4  1.5 <0.0001
CHA2DS2-VASc score <0.0001
#2 692 (33.7) 333 (28.6) 359 (34.5) 4,554 (28.7) 2,293 (28.8) 2,261 (28.6
3–4 968 (47.2) 479 (48.9) 489 (46.9) 7,662 (48.3) 3,801 (47.8) 3,861 (48.9)
$5 391 (19.1) 197 (22.5) 194 (18.6) 3,640 (23.0) 1,860 (23.4) 1,780 (22.5)
HAS-BLED score 1.6  1.0 1.6  1.0 1.6  1.0 1.8  1.1 1.8  1.0 1.8  1.1 <0.0001
HAS-BLED score <0.0001
0–1 981 (47.8) 470 (46.6) 511 (49.0) 6,270 (39.5) 3,163 (39.8) 3,107 (39.3)
2 712 (34.7) 358 (35.5) 354 (34.0) 5,790 (36.5) 2,885 (36.3) 2,905 (36.8)
$3 358 (17.5) 181 (17.9) 177 (17.0) 3,796 (23.9) 1,906 (23.9) 1,890 (23.9)
Medications at randomization
ACE inhibitor or ARB 1,544 (75.3) 763 (75.6) 781 (75.0) 1,1288 (71.2) 5,701 (71.7) 5,587 (70.7) 0.0001
Beta-blocker 1,106 (53.9) 536 (53.1) 570 (54.7) 1,0376 (65.4) 5,261 (66.1) 5,115 (64.7) <0.0001
Aspirin 742 (36.2) 377 (37.4) 365 (35.0) 4,890 (30.8) 2,482 (31.2) 2,408 (30.5) <0.0001
Clopidogrel 40 (2.0) 19 (1.9) 21 (2.0) 298 (1.9) 151 (1.9) 147 (1.9) 0.8244
Digoxin 463 (22.6) 225 (22.3) 238 (22.8) 5,365 (33.8) 2,691 (33.8) 2,674 (33.8) <0.0001
Calcium channel blocker 480 (23.4) 230 (22.8) 250 (24.0) 5,087 (32.1) 2,514 (31.6) 2,573 (32.6) <0.0001
Statin 780 (38.0) 388 (38.5) 392 (37.6) 6,693 (42.2) 3,362 (42.3) 3,331 (42.2) 0.0003
NSAID 123 (6.0) 60 (5.9) 63 (6.0) 1,397 (8.8) 692 (8.7) 705 (8.9) <0.0001
Gastric antacid drugs 348 (17.0) 170 (16.8) 178 (17.1) 3,002 (18.9) 1,513 (19.0) 1,489 (18.8) 0.0317
Theophylline 8 (0.4) 3 (0.3) 5 (0.5) 121 (0.8) 56 (0.7) 65 (0.8) 0.0601
Diuretic 1,172 (57.1) 585 (58.0) 587 (56.3) 8,531 (53.8) 4,238 (53.3) 4,293 (54.3) 0.0043
Chronic renal disease 196 (9.6) 79 (7.8) 117 (11.2) 1296 (8.2) 662 (8.3) 634 (8.0) 0.0319
Renal function 0.0158
Normal: 80 ml/min 818 (39.9) 406 (40.2) 412 (39.5) 6,576 (41.5) 3,294 (41.4) 3,282 (41.5)
Mild impairment: >50–80 ml/min 840 (41.0) 420 (41.6) 420 (40.3) 6,625 (41.8) 3,330 (41.9) 3,295 (41.7)
Moderate impairment: >30–50 ml/min 360 (17.6) 165 (16.4) 195 (18.7) 2,351 (14.8) 1,176 (14.8) 1,175 (14.9)
Severe impairment: #30 ml/min 29 (1.4) 17 (1.7) 12 (1.2) 236 (1.5) 117 (1.5) 119 (1.5)
Chronic renal disease or moderate/severe
renal function
523 (25.5) 236 (23.4) 287 (27.5) 3,382 (21.3) 1,697 (21.3) 1,685 (21.3) <0.0001
Chronic liver disease 70 (3.4) 35 (3.5) 35 (3.4) 439 (2.8) 227 (2.9) 212 (2.7) 0.0985
Chronic liver or renal disease 563 (27.5) 255 (25.3) 308 (29.6) 3,682 (23.2) 1,853 (23.3) 1,829 (23.1) <0.0001
Values are median (25th, 75th percentiles), n (%), or mean  SD. *For comparison between amiodarone patients (n ¼ 2,051) and no amiodarone patients (n ¼ 15,856).
ACE¼ angiotensin-converting enzyme; AF¼ atrial ﬁbrillation; ARB¼ angiotensin II receptor blocker; BMI¼ body mass index; BP¼ blood pressure; CABG¼ coronary artery bypass grafting; CAD¼ coronary
artery disease; CHADS2 ¼ congestive heart failure, hypertension, age, diabetes, and stroke; CHA2DS2-VASc ¼ congestive heart failure/LV dysfunction, hypertension, age $75 years, diabetes mellitus, stroke/
TIA/thromboembolism, vascular disease, age 65-74 years, sex; HAS-BLED ¼ hypertension, abnormal liver/renal function, stroke, bleeding history or predisposition, labile international normalized ratio,
elderly (age $65 years), drugs/alcohol concomitantly; HF ¼ heart failure; ICD ¼ implantable cardioverter deﬁbrillator; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NSAID ¼
nonsteroidal anti-inﬂammatory drugs; NYHA ¼ New York Heart Association; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; SE ¼ systemic embolism; TIA ¼ transient ischemic
attack; VF ¼ ventricular ﬁbrillation; VKA ¼ vitamin K antagonist; VT ¼ ventricular tachycardia.
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1545America, 12% in Europe, 9.5% in the Asian Paciﬁc
countries, and 6.6% in North America.
In general, patients who received amiodarone were
younger (median age 68 years vs. 70 years; p < 0.001),
were more likely to have heart failure or a reduced
LVEF (44.4% vs. 34.3%; p< 0.0001), were less likely to
have diabetes (21.8% vs. 25.6%; p ¼ 0.0003), and were
less likely to have had a previous stroke, TIA, or sys-
temic embolism (15.7% vs. 19.9%; p < 0.0001). TheCHADS2 score was 2.0  1.0 for patients on amiodar-
one and 2.1  1.1 for patients not on amiodarone (p ¼
0.0003). The CHA2DS2-VASc score was 3.2  1.5 for
patients on amiodarone and 3.4  1.5 for patients not
on amiodarone. More patients on amiodarone had
paroxysmal AF compared with those not on amio-
darone (34.2% vs. 12.8%; p < 0.0001).
In patients assigned to warfarin, the mean TTR was
56.5% in patients who received amiodarone and
TABLE 2 Observed R
and by Study Drug As
Event
Efﬁcacy endpoints
Stroke or SE
All-cause death
CV death
Non-CV death
MI
Safety endpoints
Major bleeding
Major/CRNM bleedin
Intracranial bleeding
Values are %/year (n). *Ha
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FIGURE 1 Kaplan-Meier Curves of Stroke or Systemic Embolism
Stroke or systemic embolism by amiodarone use at randomization in patients treated with
apixaban or warfarin. RRR ¼ relative risk ratio.
Flaker et al. J A C C V O L . 6 4 , N O . 1 5 , 2 0 1 4
Amiodarone in AF and Anticoagulation O C T O B E R 1 4 , 2 0 1 4 : 1 5 4 1 – 5 0
154663.0% in patients who did not receive amiodarone
(p < 0.0001). For those patients who received amio-
darone versus those who did not, the mean times of
follow-up below range (INR <2) were 28.5% and
24.2%, respectively (p < 0.0001). The mean times of
follow-up above range (INR >3) were 15% and 12.8%,
respectively (p < 0.0001).
APIXABAN VERSUS WARFARIN. Of the 2,051 pa-
tients who received amiodarone at baseline, 1,009
patients were assigned to apixaban and 1,042 were
assigned to warfarin. There were no signiﬁcant dif-
ferences in selected stroke risk factors or in selected
bleeding risk factors between patients receiving
either apixaban or warfarin (Table 1).
For patients who received amiodarone, the rate of
stroke or systemic embolism was 1.24%/year forates and Number of Events for Efﬁcacy and Safety Endpoints in Patients
signment
Amiodarone
Overall Apixaban Warfarin HR (95% CI)* Over
1.55 (58) 1.24 (23) 1.85 (35) 0.68 (0.40–1.15) 1.43 (4
4.91 (187) 4.15 (78) 5.65 (109) 0.74 (0.55–0.98) 3.56 (1
2.63 (100) 2.34 (44) 2.90 (56) 0.81 (0.54–1.20) 1.82 (5
1.58 (60) 1.38 (26) 1.76 (34) 0.79 (0.47–1.31) 1.13 (3
0.27 (10) 0.21 (4) 0.32 (6) 0.68 (0.19–2.41) 0.61(1
2.46 (82) 1.86 (31) 3.06 (51) 0.61 (0.39–0.96) 2.60 (6
g 5.12 (167) 3.92 (64) 6.31 (103) 0.63 (0.46–0.86) 4.99 (1
0.74 (25) 0.30 (5) 1.19 (20) 0.25 (0.10–0.67) 0.54 (1
zard ratios are apixaban versus warfarin.
; CRNM ¼ clinically relevant non-major; CV ¼ cardiovascular; HR ¼ hazard ratio; other abbrpatients assigned to apixaban and 1.85%/year for
patients assigned towarfarin (HR: 0.68, 95%CI: 0.40 to
1.145). In patients who did not receive amiodarone, the
rate of stroke or systemic embolism was 1.29%/year
when assigned to apixaban and 1.57%/year when
assigned to warfarin (HR: 0.82; 95% CI: 0.68 to 1.00)
(Figure 1, Table 1). The interaction p value was 0.4776.
For patients who received amiodarone, the rate of all-
cause death was 4.15%/year when assigned to apix-
aban and 5.65%/year when assigned to warfarin (HR:
0.74; 95% CI: 0.55 to 0.98). In patients who did not
receive amiodarone, the rate of all-cause death was
3.43%/yearwhen assigned to apixaban and 3.68%/year
when assigned to warfarin (HR: 0.93; 95% CI: 0.83 to
1.05). The interaction p value was 0.1366. Other efﬁ-
cacy analyses, including rates of cardiovascular death
and noncardiovascular death, are shown in Table 2.
In terms of safety endpoints, in patients who
received amiodarone at baseline, the rate of major
bleeding was 1.86%/year when assigned to apixaban
and 3.06%/year when assigned to warfarin (HR: 0.61;
95% CI: 0.39 to 0.96). In patients who did not receive
amiodarone at baseline, the rate of major bleeding
was 2.18%/year when assigned to apixaban and
3.03%/year in patients assigned to warfarin (HR: 0.72;
95% CI: 0.62 to 0.84) (Figure 2). The interaction
p value was 0.4894. The rates of combined major and
clinically relevant nonmajor bleeding in patients who
received and did not receive amiodarone at baseline
are shown in Table 2.
MAJOR EVENTS ASSOCIATED WITH THE USE OF
AMIODARONE. Using a propensity score–adjusted
analysis, patients who received amiodarone had a
signiﬁcantly higher rate of stroke or systemic embo-
lism compared with those who did not receiveWith Amiodarone and No Amiodarone at Randomization
No Amiodarone
Interaction
p Valueall Apixaban Warfarin HR (95% CI)*
16) 1.29 (189) 1.57 (227) 0.82 (0.68–1.00) 0.4776
060) 3.43 (514) 3.68 (546) 0.93 (0.83–1.05) 0.1366
41) 1.74 (260) 1.90 (281) 0.92 (0.77–1.09) 0.5611
35) 1.10 (165) 1.15 (170) 0.96 (0.78–1.19) 0.4728
79) 0.58 (85) 0.65 (94) 0.90 (0.90–1.20) 0.6790
90) 2.18 (293) 3.03 (397) 0.72 (0.62–0.84) 0.4894
298) 4.10 (542) 5.92 (756) 0.70 (0.62–0.78) 0.5226
46) 0.35 (47) 0.74 (99) 0.46 (0.33–0.66) 0.2456
eviations as in Table 1.
TABLE 3 Observed Rates and Number of Events in Patients Included in the
Propensity-Matched Analysis*
Endpoint
Amiodarone Rates
(Events)
No Amiodarone Rates
(Events) HR (95% CI)† p Value
Stroke/SE 1.58 (50) 1.19 (115) 1.47 (1.03–2.10) 0.0322
All-cause death‡ 4.76 (156) 4.09 (409) 1.16 (0.95–1.41) 0.1577
CV death‡ 2.65 (87) 2.26 (226) 1.19 (0.91–1.55) 0.2104
Non-CV death‡ 1.49 (49) 1.09 (109) 1.27 (0.88–1.82) 0.1964
MI 0.30 (10) 0.51 (51) 0.58 (0.27–1.25) 0.1646
Major bleeding 2.40 (74) 2.09 (199) 1.15 (0.85–1.53) 0.3656
Values are n (%). Rate per 100 patient-years of follow-up in patients included in this analysis. Patients on
amiodarone were matched with patients not on amiodarone in 1:3 ratio on the basis of variables associated with
each endpoint. Sample sizes were: 1,755 amiodarone/5,265 nonamiodarone for stroke/SE; 1,780 amiodarone/
5,340 nonamiodarone for all-cause, CV and non-CV death; 1,818 amiodarone/5,454 nonamiodarone for
myocardial infarction; and 1,828 amiodarone/5,484 nonamiodarone for major bleeding. *Patients from the
following countries were excluded from this analysis: Finland, Hong Kong, Malaysia, Norway, Puerto Rico,
Singapore, Sweden, and Turkey. †The hazard ratios compare amiodarone with no amiodarone. ‡Causes of death
are classiﬁed as CV, non-CV, and unknown cause.
Abbreviations as in Tables 1 and 2.
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FIGURE 2 Kaplan-Meier Curves of Major Bleeding
International Society of Thrombosis and Hemostasis (ISTH) major bleeding by amiodarone
use at randomization in patients treated with apixaban or warfarin. Abbreviation as in
Figure 1.
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1547amiodarone. The rate of stroke or systemic embolism
was 1.58%/year in patients who received amiodarone
and 1.19% in those who did not receive amiodarone
(adjusted HR: 1.47; 95% CI: 1.03 to 2.10; p ¼ 0.0322).
Patients who received amiodarone had numerically,
but not signiﬁcantly, higher rates of all-cause death
(4.76% vs. 4.09%; adjusted HR: 1.16; 95% CI: 0.95 to
1.41), cardiovascular death (2.65% vs. 2.26%; adjusted
HR: 1.2; 95% CI: 0.91 to 1.55), and noncardiovascular
death (1.49% vs. 1.09%; HR: 1.27; 95% CI: 0.88 to 1.82).
There were no signiﬁcant differences in MI and major
bleeding between those who received and those who
did not receive amiodarone (Table 3).
DISCUSSION
This analysis from the ARISTOTLE study included
2,051 patients who received amiodarone, which rep-
resented one of the largest experiences to date with
amiodarone for AF in a clinical trial. The main ﬁnd-
ings were as follows: 1) amiodarone use was associ-
ated with a signiﬁcantly increased risk of stroke and
systemic embolism, and a lower time in the TTR
when used with warfarin; 2) apixaban consistently
reduced the rate of stroke and systemic embolism,
death, and major bleeding compared with warfarin in
amiodarone patients and patients not on amiodarone
(Central Illustration); and 3) the relative reductions in
stroke and systemic embolism, mortality, and major
bleeding with apixaban compared with warfarin were
similar with and without amiodarone use.
The quality of anticoagulation, as assessed by the
mean TTR during the trial, was 56.5% in patients
treated with warfarin combined with amiodarone.
In clinical trials, TTR values of 62% to 66% were ach-
ieved (19–22), and were accepted as an indication of
effective anticoagulation. In ARISTOTLE, the mean
TTR was 63% in patients who did not receive amio-
darone andwhowere assigned to warfarin. Despite the
difference in TTR, therewas a consistent risk reduction
in stroke and systemic embolism, mortality, andmajor
bleeding with apixaban compared with warfarin,
regardless of treatment with amiodarone. These ﬁnd-
ings were in accordance with our previous observation
on the lack of interaction between INR control and the
beneﬁts of apixaban compared with warfarin in the
overall ARISTOTLE trial (23). These data suggested
that apixaban is an attractive choice to prevent stroke
and systemic embolism, lower mortality, and reduce
major bleeding, irrespective of whether the patient
receives or does not receive amiodarone.
The use of class IA antiarrhythmic drugs in AF has
been associated with excess mortality (24,25).
Whether class IC or class III agents, includingamiodarone, are associated with higher mortality in
patients with AF has been controversial. Excess
mortality has not been noted in a pooled analysis of
class IC and class III drugs after cardioversion (26).
However, antiarrhythmic drug therapy in the AFFIRM
study, which included amiodarone, sotalol, and
6 class I antiarrhythmic drugs, was associated with
excess mortality (27), and noncardiovascular mortal-
ity was increased in patients on amiodarone (15,16).
Reports of increased cancer rates with amiodarone
have been published (13,14).
Despite these concerns, the use of amiodarone in
ARISTOTLE was substantial; 11% of patients received
this drug. There was wide geographic variability in
amidarone use; its use was more likely in Latin
America and less likely in North America. The reason
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CENTRAL ILLUSTRATION Patient Outcomes by Amiodarone Use at Randomization
Event rates and hazard ratios (HRs) comparing apixaban to warfarin by amiodarone use at randomization. CV ¼ cardiovascular; SE ¼ systemic
embolism.
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1548for these differences was uncertain, but it might
represent differences in the patient population,
regional differences in perceptions about the merits
of rhythm control, or differences in the availability of
catheter-based techniques for rhythm control.
The reason for the suggestion of a higher rate of
stroke and systemic embolism in patients who
received amiodarone versus patients who did not
receive amiodarone is unclear. There is no a priori
reason for class III antiarrhythmic medications to be
thrombogenic. In the AFFIRM study, amiodarone was
the most frequently used medication in the rhythm
control arm, and there were no differences in cere-
brovascular events in patients assigned to the rhythm
control arm compared with the rate control arm (15).
The multichannel blocker, dronedarone, with class III
properties and negligible effects on INR values, was
associated with a reduction in stroke in patients with
paroxysmal or persistent AF (28), but was also asso-
ciated with an increased stroke risk in patients with
permanent AF (29). These data suggest that the
thromboembolic risk is likely related to characteris-
tics of the AF population, rather than the speciﬁc
antiarrhythmic drug. In the present analysis, the
mean TTR in patients who received amiodarone and
warfarin was low, and the majority of values were
below the accepted therapeutic range. It is possible
that less effective anticoagulation with amiodarone
could contribute to the observed association withstroke or systemic embolism in the warfarin group,
where the HR for stroke or systemic embolism with
amiodarone was somewhat greater, although there
was no signiﬁcant interaction. These ﬁndings indicate
that special efforts are needed to maintain an in-
range INR in patients who receive warfarin and
amiodarone. These ﬁndings provide an additional
rationale to prefer apixaban more than warfarin in
patients who require amiodarone.
The concern about cancer and amiodarone use in
humans was based on the results from a meta-
analysis of 15 trials, 4 of which reported cancer
deaths. Of 1,609 patients who received amiodarone,
13 (0.8%) died of cancer. In comparison, of 1,597 pa-
tients who received placebo, 4 (0.3%) died of cancer
(13). A more recent retrospective cohort study from
Taiwan included patients who received amiodarone
for >28 days without antecedent malignancy (14). Of
6,418 patients followed for a median of 2.57 years,
280 cancers developed, which was higher than would
be expected. Cancer was not an endpoint of the
ARISTOTLE trial, and the follow-up time was rela-
tively brief for the detection of any possible associa-
tion of amiodarone with cancer.
STUDY LIMITATIONS. This was a retrospective eval-
uation of the ARISTOTLE database; therefore, it was
subject to all the biases inherent to this type of
analysis. Amiodarone use was deﬁned at the time of
randomization, and its use was not systematically
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Amiodarone is
effective in preventing AF, but it can interfere with warfarin
metabolism and potentially increase the risk of thromboembolic
events or bleeding. Newer target-speciﬁc oral anticoagulants
have less interaction with amiodarone.
COMPETENCY IN MEDICAL KNOWLEDGE 2: Compared
with warfarin, in the ARISTOTLE trial, the factor Xa inhibitor,
apixaban, reduced rates of stroke and systemic embolism, death,
and major bleeding in patients with nonvalvular AF, whether or
not they were concurrently treated with amiodarone.
TRANSLATIONAL OUTLOOK: Randomized studies of amio-
darone and other antiarrhythmic medications in anticoagulated
patients with AF could clarify the generalizability of these ﬁnd-
ings and better guide treatment decisions in clinical practice.
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1549collected throughout the study. The duration of
amiodarone use before entry into the study was not
determined. At baseline, patients were classiﬁed with
either paroxysmal or persistent and/or permanent AF,
and patients with persistent and permanent AF were
not separated into different groups. Patients who did
not receive amiodarone at the time of randomization
might have received it in the past. The follow-up was
too brief to detect important long-term problems with
the medication, including the development of cancer.
Finally, because patients who received or did not
receive amiodarone were not randomized, there were
important differences between them. Although we
attempted to compensate for these differences with a
propensity score method, assumptions were made in
the development of this scoring system, and there
might have been residual unmeasured confounding.
Therefore, the possibility of confounding factors or
even the play of chance as a cause for the associations
between amiodarone use and outcomes could not be
excluded.
CONCLUSIONS
In a contemporary clinical trial involving patients
with AF at risk for stroke, amiodarone use was
substantial and varied by geographic region. Anti-
coagulation quality, as assessed by TTR, was lower in
warfarin-treated patients who received amiodarone,
and amiodarone use was associated with a signiﬁ-
cantly higher risk of stroke and systemic embolism.The relative effects of apixaban versus warfarin on
stroke and systemic embolism, mortality, and major
bleeding were consistent in patients who received
and patients who did not receive amiodarone.
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